Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - GenStar Therapeutics Corp (AMEX:GNT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider
Recent Events
July 24Price hit new 52-week low ($1.90)
Location
10865 Altman Row
San Diego, CA 92121
Phone: (858) 450-5949
Fax: (858) 450-0425
Employees (last reported count): 53
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 23%
·Over the last 6 months:
 · one insider sell; 56.0K shares
  (1.0% of insider shares)
·Institutional: 35% (45% of float)
(31 institutions)
·Net Inst. Buying: 418.0K shares (+4.90%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
GenStar Therapeutics Corporation is a biotechnology company dedicated to the development of gene therapy products capable of treating a wide range of serious diseases. These range from liver-based diseases such as hemophilia, to various types of cancer and infectious diseases that include HIV and AIDS. The Company is currently focusing on developing proprietary adenoviral and lentiviral vector technologies that will become products for the treatment of hemophilia, prostate cancer and HIV/AIDS. GenStar's novel core technology is the Maximum-AD system, which is based on common cold adenoviral vector systems that facilitate maximum therapeutic DNA delivery. Maximum-AD has been bioengineered from the common cold adenovirus, with all viral genes removed to provide safety and maximum capacity for gene delivery.
More from Market Guide: Expanded Business Description

Financial Summary
GeneStar Therapeutics Corp. is a biotechnology company dedicated to the development of innovative gene therapy products for the treatment of hemophilia, cancer and HIV/AIDS. For the six months ended 6/30/01, revenues fell 1% to $72 thousand. Net loss rose 22% to $5.6 million. Results reflect decreased research agreement and grant revenues. Higher loss reflects the expenses for the Company's efforts to develop core technologies and products.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

Paul Quadros, 53
Chairman
$134K
Robert Sobol, M.D., 47
CEO, Director
231K
Lee McCracken
Pres and CBO
--  
Wei-Wei Zhang, Ph.D., 42
Sr. VP, CSO
272K
Connie Kohne
VP, Regulatory Affairs and Corp. Quality
--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:GNTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 24-July-2001
$1.90 
Recent Price$4.16 
52-Week High
on 7-Nov-2000
$13.438
Beta-2.81 
Daily Volume (3-month avg)69.3K
Daily Volume (10-day avg)37.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-52.1%
52-Week Change
relative to S&P500
-35.8%
Share-Related Items
Market Capitalization$97.0M
Shares Outstanding23.3M
Float17.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.73 
Earnings (ttm)-$0.47 
Earnings (mrq)-$0.13 
Sales (ttm)$0.01 
Cash (mrq)$0.88 
Valuation Ratios
Price/Book (mrq)5.69 
Price/EarningsN/A 
Price/Sales (ttm)586.20 
Income Statements
Sales (ttm)$161.0K
EBITDA (ttm)-$10.2M
Income available to common (ttm)-$10.6M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-42.58%
Return on Equity (ttm)-57.21%
Financial Strength
Current Ratio (mrq)15.72 
Debt/Equity (mrq)0.09 
Total Cash (mrq)$20.1M
Short Interest
As of 8-Aug-2001
Shares Short17.0K
Percent of Float0.1%
Shares Short
(Prior Month)
17.0K
Short Ratio0.23 
Daily Volume74.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.